drugset
Drugs / IONIS FXI-LRX
last change Apr 2019 re-read 3 minutes ago

IONIS FXI-LRX

also known as ION-957943

Antisense oligonucleotide

Investigated by
Ionis Pharmaceuticals, Inc.

Trials 1

today NCT03582462 · Ph 1
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03582462 Jul 2018 → Apr 2019 — Ionis Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IONIS FXI-LRX “ION-957943 (IONIS FXI-LRX, a GalNAc Conjugated 2'-MOE Chimeric Antisense Oligonucleotide Inhibitor of Factor XI)” NCT03582462 ↗
1

NCT03582462 ↗
Known as ION-957943 “ION-957943 (IONIS FXI-LRX, a GalNAc Conjugated 2'-MOE Chimeric Antisense Oligonucleotide Inhibitor of Factor XI)” NCT03582462 ↗
Action Inhibit “a GalNAc Conjugated 2'-MOE Chimeric Antisense Oligonucleotide Inhibitor of Factor XI” NCT03582462 ↗
Modality Antisense oligonucleotide “a GalNAc Conjugated 2'-MOE Chimeric Antisense Oligonucleotide Inhibitor of Factor XI” NCT03582462 ↗
Route Subcutaneous “by subcutaneous (SC) injection” NCT03582462 ↗